UCB (OTCMKTS:UCBJY) Hits New 12-Month High – What’s Next?

UCB SA (OTCMKTS:UCBJY)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $156.07 and last traded at $155.70, with a volume of 1207 shares changing hands. The stock had previously closed at $152.0250.

Wall Street Analysts Forecast Growth

UCBJY has been the topic of several recent analyst reports. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research note on Sunday, October 26th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

UCB Price Performance

The firm’s fifty day moving average price is $142.20 and its 200 day moving average price is $129.75.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.